Eli Lilly and Company
LLY
$734.39
-$11.31-1.52%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -1.53% | 14.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.53% | 14.27% | |||
| Cost of Revenue | -3.88% | 2.92% | |||
| Gross Profit | -0.96% | 17.43% | |||
| SG&A Expenses | 7.18% | -6.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.40% | -0.27% | |||
| Operating Income | -9.82% | 51.43% | |||
| Income Before Tax | 487.27% | -79.55% | |||
| Income Tax Expenses | -34.15% | 48.79% | |||
| Earnings from Continuing Operations | 3,914.81% | -103.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3,914.81% | -103.26% | |||
| EBIT | -9.82% | 51.43% | |||
| EBITDA | -9.39% | 46.12% | |||
| EPS Basic | 3,896.71% | -103.26% | |||
| Normalized Basic EPS | -11.59% | 53.93% | |||
| EPS Diluted | 3,891.22% | -103.27% | |||
| Normalized Diluted EPS | -11.59% | 54.45% | |||
| Average Basic Shares Outstanding | 0.46% | 0.01% | |||
| Average Diluted Shares Outstanding | 0.46% | -0.32% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | 1.03% | -31.67% | |||
